GlassScriptPhysician profile
John Michael Kennedy
NPI 1912095787
$1,840.30
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.53 · 2021: $23.93 · 2022: $320 · 2023: $1,093 · 2024: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $95.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.62 |
| Education | $95.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $375.00 | 2023 | Myrisk |
| Pfizer INC. | $173.79 | 2023-2024 | |
| Blueprint Medicines Corporation | $135.00 | 2022 | |
| Cti Biopharma Corp. | $132.35 | 2023 | Vonjo |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Beigene USA, INC. | $81.88 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $80.53 | 2022-2024 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $63.78 | 2023-2024 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $57.77 | 2023-2024 | Opdualag |
| Merck Sharp & Dohme LLC | $50.43 | 2019-2023 | Keytruda |
| Abbvie INC. | $49.31 | 2024 | |
| Myovant Sciences INC. | $47.69 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.50 | 2023-2024 | Jemperli, Zejula |
| Mirati Therapeutics, INC. | $36.24 | 2023 | Krazati |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.63 | 2024 | |
| Stemline Therapeutics INC. | $33.30 | 2023 | Orserdu |
| Sobi, INC | $24.20 | 2024 | |
| Incyte Corporation | $21.98 | 2023 | Monjuvi |
| Amgen INC. | $21.82 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $21.66 | 2023 | Imbruvica |
| Foundation Medicine, INC. | $19.01 | 2023 | |
| Seagen INC. | $18.51 | 2019 | |
| Coherus Oncology, INC. | $18.44 | 2024 | |
| Daiichi Sankyo INC. | $16.53 | 2024 | Injectafer |
| Apellis Pharmaceuticals, INC. | $16.12 | 2023 | Empaveli |
| Eisai INC. | $12.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.